PSA-Oxyntomodulin: Phase I data

A placebo-controlled, Russian Phase I trial in 12 healthy volunteers showed that single doses of 0.25, 0.75 and 1.5 mg/kg subcutaneous PSA-Oxyntomodulin were well tolerated. The trial was conducted by...